Clinical trials: Epithelial Tumor
Glioblastoma Multiforme
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801.
- Trial name
- NCT05222802
- Testing
- ERAS-801
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Katmai Pharmaceuticals Inc.
Endometrial Cancer, Uterine Cancer
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
- Conditions
- Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma
- Trial name
- P204 (NCT03395080)
- Testing
- Paclitaxel, 300mg DKN-01, 600mg DKN-01
- Where
- 17 sites in United States
- Volunteers
- 111 people
- Sponsor
- Leap Therapeutics, Inc.
Urothelial Carcinoma
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.
- Trial name
- PREVAIL (NCT03788746)
- Where
- 58 sites in United States
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
This is an external control, observational, retrospective study designed to compare clinical outcomes for pralsetinib compared with best available therapy for patients with RET-fusion positive advanced NSCLC.
- Conditions
- RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms
- Trial name
- NCT04697446
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 279 people
- Sponsor
- Blueprint Medicines Corporation
Hepatocellular Carcinoma
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
The purpose of this open-label, randomized, phase II study is to compare the safety and efficacy of dovitinib versus sorafenib as first-line treatment in adult patients with advanced Hepatocellular Carcinoma (HCC).
- Trial name
- NCT01232296
- Testing
- dovitinib, sorafenib
- Where
- 24 sites in China, Hong Kong and 5 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Carcinoma, Hepatocellular
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no…
- Trial name
- IMbrave150 (NCT03434379)
- Testing
- Atezolizumab, Bevacizumab, Sorafenib
- Where
- 119 sites in United States, Australia and 15 more
- Volunteers
- 558 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer Transitional Cell Carcinoma
Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology
This study includes two semi-consecutive parts: Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.
- Trial name
- NCT01551342
- Where
- 7 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Zetiq Technologies
Metastatic Renal Cell Carcinoma
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®.
- Trial name
- NCT00684645
- Testing
- SUTENT
- Where
- 20 sites in Czechia
- Volunteers
- 186 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of Head and Neck
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT04183166
- Testing
- TG4050
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Transgene
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Patients With Non-curable Head and Neck Cancer
The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer
- Trial name
- NCT00382031
- Testing
- Zalutumumab, Control
- Where
- 82 sites in Belgium, Brazil and 10 more
- Volunteers
- 286 people
- Sponsor
- Genmab
Liver Tumors, HCC - Hepatocellular Carcinoma
Needle-based Percutaneous Ablation of Liver Tumors.
The goal of this clinical trial is to learn if INT001 can ablate liver tumors in adults in an outpatient setting. It will also help us learn about the safety of INT001. The main questions it aims to answer are: 1.
- Conditions
- Liver Tumors, HCC - Hepatocellular Carcinoma, Metastatic Liver Tumor
- Trial name
- NCT06689670
- Testing
- Needle based delivery of INT001 into liver tumors under real-time image guidance
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- inTumo Therapeutics, Inc.
Brain Tumor, Brain Tumor, Recurrent
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Brain Cancer
- Trial name
- NCT00747253
- Testing
- AutoLITT system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Monteris Medical
Ovarian Cancer, Endometrial Cancer
Registry Platform Ovarian and Endometrial Cancer
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Ovary Neoplasm, Endometrial Neoplasms
- Trial name
- SMARAGD (NCT05129969)
- Testing
- Physician's choice according to patient's needs.
- Where
- Germany
- Volunteers
- 1,975 people
- Sponsor
- iOMEDICO AG
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Glioblastoma, Small Cell Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ACT IV (NCT01480479)
- Testing
- Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
- Where
- 223 sites in United States, Australia and 22 more
- Volunteers
- 745 people
- Sponsor
- Celldex Therapeutics
Squamous Cell Carcinoma of the Head and Neck
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
The primary purpose of this trial is to assess the safety and tolerability of EMD 1201081, a novel immunomodulatory agent that is an agonist of TLR9, in combination with 5-FU/cisplatin and cetuximab in first line treatment of…
- Trial name
- NCT01360827
- Testing
- EMD 1201081 + 5-FU + Cisplatin + Cetuximab
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ependymoma
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in…
- Trial name
- NCT01247922
- Testing
- Erlotinib
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 4 people
- Sponsor
- OSI Pharmaceuticals
Hepatocellular Carcinoma
Trial of TRC105 and Sorafenib in Patients With HCC
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma.
- Trial name
- NCT02560779
- Testing
- Carotuximab (TRC105), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Carcinoma, Renal Cell
Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
- Trial name
- NEXST (NCT01557127)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Poland
- Volunteers
- 205 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.